Skip to main content

HoLEP Double-n Technology Promising for Benign Prostatic Hyperplasia

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 6, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Feb. 6, 2025 -- For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology shows promise for improving urinary symptoms while better preserving ejaculatory function, according to a study published online Jan. 10 in the World Journal of Urology.

Zhixiang Gao, from Zhangjiagang Hospital Affiliated to Soochow University in Suzhou, China, and colleagues conducted a multicenter, prospective, single-blind, randomized controlled trial involving sexually active men with BPH. Participants were randomly allocated to standard HoLEP, single-n technology, and innovative double-n technology (groups A, B, and C, respectively). A total of 139 participants completed the study.

The researchers found that all groups had significant improvements in maximum urinary flow rate and the International Prostate Symptom Score. Across all groups, there were initial declines in International Index of Erectile Function scores, stabilizing to baseline by three months, with no additional improvement observed. Modest antegrade ejaculation rates were seen in group A, starting at 15.4 percent at three months and reaching 23.1 percent at 12 months. In groups B and C, significant improvement was seen, with antegrade ejaculation rates increasing from 31.8 to 45.5 percent and from 57.8 to 77.8 percent, respectively. Group A had 100 percent semen reduction at three months, decreasing to 77.8 percent at 12 months. A similar trend was seen in Group B (100 and 68.2 percent, respectively), while a more pronounced decline was seen in Group C, from 84.6 to 37.1 percent, respectively.

"The Double-n HoLEP represents a significant step forward in the surgical management of BPH, especially for patients concerned about preserving sexual function postoperatively," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted February 2025

Read this next

FDA Approves Gemtesa for Overactive Bladder in Men With BPH

THURSDAY, Jan. 2, 2025 -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic...

Comparable Results Seen for HoLEP With, Without Preservation of Urethral Mucosa in BPH

THURSDAY, Dec. 5, 2024 -- For patients with benign prostatic hyperplasia (BPH), holmium laser enucleation of the prostate (HoLEP) with preservation of the urethral mucosa from...

Long-Term Complications After Prostate Cancer Treatment Not Uncommon

FRIDAY, Nov. 8, 2024 -- Prostate cancer (PCA) treatment is associated with increased rates of complications in the 12 years after treatment, according to a study published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.